Modarress M, Maghami F Q, Golnavaz M, Behtash N, Mousavi A, Khalili G R
Department of Gynecology & Obstetrics, Tehran University of Medical Science, Tehran, Iran.
Int J Gynecol Cancer. 2005 May-Jun;15(3):483-8. doi: 10.1111/j.1525-1438.2005.15312.x.
Tumor size seems to be a determinant in the prognosis of early cervical cancer. Patients with tumor greater than 4 cm (bulky) in diameter have worse outcome. The purpose of this study was to compare the efficacy of preoperative combined chemoradiation and neoadjuvant chemotherapy (NAIC) programs followed by radical hysterectomy in stage IB-IIB bulky cervical cancer. From September 1999 to April 2002, 60 patients with stage IB-IIB bulky cervical cancer were treated with preoperative external-beam radiotherapy to 45 Gy plus weekly cisplatin 50 mg/m2 or preoperative NAIC by cisplatin 50 mg/m2 and vincristin 1 mg/m2 every 7-10 days, for three courses. Surgery was performed 4-6 weeks after the completion of the preoperative treatment. There were no significant difference between age, stage, tumor size, and histopathologic type in two groups (P > 0.05). Toxicity associated with two treatment methods was usually mild. In chemoradiation group, two patients developed vesicovaginal fistula, and four patients developed long-term hydronephrosis that needed urethral stenting. Before surgery, complete and partial clinical response had no significant difference between two groups (P > 0.05). After surgery, lymph node and parametrial involvement had no significant difference between two groups (P > 0.05). In NAIC group, more patients had significantly residual tumor (P = 0.012), but residual tumor size had no significant difference between two groups (P > 0.05). Pathologic complete response was significantly higher in chemoradiation group (P = 0.004). According to the result of this study, it seems that NAIC and chemoradiation had similar effects in survival prognostic factors.
肿瘤大小似乎是早期宫颈癌预后的一个决定因素。直径大于4cm(体积较大)的肿瘤患者预后较差。本研究的目的是比较术前同步放化疗和新辅助化疗(NAIC)方案联合根治性子宫切除术治疗IB-IIB期体积较大宫颈癌的疗效。1999年9月至2002年4月,60例IB-IIB期体积较大的宫颈癌患者接受术前体外放疗至45Gy加每周顺铂50mg/m²,或术前NAIC,顺铂50mg/m²,长春新碱1mg/m²,每7-10天一次,共三个疗程。术前治疗完成后4-6周进行手术。两组患者在年龄、分期、肿瘤大小和组织病理学类型方面无显著差异(P>0.05)。两种治疗方法相关的毒性通常较轻。在同步放化疗组,2例患者出现膀胱阴道瘘,4例患者出现需要尿道支架置入的长期肾盂积水。术前,两组患者的完全和部分临床缓解无显著差异(P>0.05)。术后,两组患者的淋巴结和宫旁组织受累情况无显著差异(P>0.05)。在NAIC组,更多患者有明显残留肿瘤(P=0.012),但两组之间残留肿瘤大小无显著差异(P>0.05)。同步放化疗组的病理完全缓解率显著更高(P=0.004)。根据本研究结果,NAIC和同步放化疗在生存预后因素方面似乎有相似的效果。